Management of viral infections in solid organ transplant recipients

References

• Razonable RR, Eid AJ. Viral infections in transplant recipients. Minerva Med.100(6), 479–501 (2009).
   PubMed Web of Science ®Google Scholar
• Fischer SA, Graham MB, Kuehnert MJ et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med.354(21), 2235–2249 (2006).
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Burton EC, Kuehnert MJ et al. Transmission of rabies virus from an organ donor to four transplant recipients. N. Engl. J. Med.352(11), 1103–1111 (2005).
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Jernigan DB, Guasch A et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N. Engl. J. Med.348(22), 2196–2203 (2003).
   PubMed Web of Science ®Google Scholar
• Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes15(1), 4–12 (2008).
   PubMedGoogle Scholar
• Abdel Massih RC, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J. Gastroenterol.15(21), 2561–2569 (2009).
   PubMed Web of Science ®Google Scholar
• Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm.62(8 Suppl. 1), S7–S13 (2005).
   Web of Science ®Google Scholar
• Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27–29 February 2004. Herpes11(3), 77–86 (2004).
   PubMedGoogle Scholar
• Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein–Barr virus infections. Herpes10(3), 60–65 (2003).
   PubMedGoogle Scholar
• Kim WR. The burden of hepatitis C in the United States. Hepatology36(5 Suppl. 1), S30–S34 (2002).
   PubMed Web of Science ®Google Scholar
• Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl.10(8), 968–974 (2004).
   PubMed Web of Science ®Google Scholar
• Watt K, Veldt B, Charlton M. A Practical Guide to the Management of HCV Infection Following Liver Transplantation. Am. J. Transplant.9(8), 1707–1713 (2009).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Burak KW, van Cruijsen H et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin. Infect. Dis.35(8), 974–981 (2002).
   PubMed Web of Science ®Google Scholar
• Burak KW, Kremers WK, Batts KP et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl.8(4), 362–369 (2002).
   PubMed Web of Science ®Google Scholar
• Cummins NW, Deziel PJ, Abraham RS, Razonable RR. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl. Infect. Dis.11(1), 20–27 (2009).
   PubMed Web of Science ®Google Scholar
• Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl.13(12), 1703–1709 (2007).
   PubMed Web of Science ®Google Scholar
• Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis.46(6), 840–846 (2008).
   PubMed Web of Science ®Google Scholar
• Kijpittayarit S, Deziel P, Eid AJ, Razonable RR. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation81(1), 137–138 (2006).
   PubMed Web of Science ®Google Scholar
• Kijpittayarit-Arthurs S, Eid AJ, Kremers WK et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J. Heart Lung Transplant.26(10), 1019–1024 (2007).
   PubMed Web of Science ®Google Scholar
• Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin. Transplant.22(2), 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl. Infect. Dis.10(1), 13–18 (2008).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin. Respir. Crit. Care Med.28(2), 222–242 (2007).
   PubMed Web of Science ®Google Scholar
• Englund JA, Boeckh M, Kuypers J et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann. Intern. Med.144(5), 344–349 (2006).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. Infect. Dis.192(8), 1331–1339 (2005).
   PubMed Web of Science ®Google Scholar
• Schillinger JA, Xu F, Sternberg MR et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976–1994. Sex. Transm. Dis.31(12), 753–760 (2004).
   PubMed Web of Science ®Google Scholar
• Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA296(8), 964–973 (2006).
   PubMed Web of Science ®Google Scholar
• Greenberg MS, Friedman H, Cohen SG, Oh SH, Laster L, Starr S. A comparative study of herpes simplex infections in renal transplant and leukemic patients. J. Infect. Dis.156(2), 280–287 (1987).
   PubMed Web of Science ®Google Scholar
• Dummer JS, Armstrong J, Somers J et al. Transmission of infection with herpes simplex virus by renal transplantation. J. Infect. Dis.155(2), 202–206 (1987).
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med.340(19), 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Seale L, Jones CJ, Kathpalia S et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA254(24), 3435–3438 (1985).
   PubMed Web of Science ®Google Scholar
• Zuckerman R, Wald A. Herpes simplex virus infections in solid organ transplant recipients. Am. J. Transplant9(Suppl. 4), S104–S107 (2009).
   PubMedGoogle Scholar
• Pettersson E, Hovi T, Ahonen J et al. Prophylactic oral acyclovir after renal transplantation. Transplantation39(3), 279–281 (1985).
   PubMed Web of Science ®Google Scholar
• Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J. Infect. Dis.188(9), 1345–1351 (2003).
   PubMed Web of Science ®Google Scholar
• Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N. Engl. J. Med.347(5), 340–346 (2002).
   PubMed Web of Science ®Google Scholar
• Geel AL, Landman TS, Kal JA, van Doomum GJ, Weimar W. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant. Proc.38(10), 3418–3419 (2006).
   PubMed Web of Science ®Google Scholar
• Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am. J. Transplant.4(1), 108–115 (2004).
   PubMed Web of Science ®Google Scholar
• Allen U, Preiksaitis J. Epstein–Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S87–S96 (2009).
   PubMed Web of Science ®Google Scholar
• Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin. Infect. Dis.20(5), 1346–1353 (1995).
   PubMed Web of Science ®Google Scholar
• Walker RC, Paya CV, Marshall WF et al. Pretransplantation seronegative Epstein–Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J. Heart Lung Transplant.14(2), 214–221 (1995).
   PubMed Web of Science ®Google Scholar
• Green M. Management of Epstein–Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am. J. Transplant.1(2), 103–108 (2001).
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG. Interlaboratory comparison of Epstein–Barr virus viral load assays. Am. J. Transplant.9(2), 269–279 (2009).
   PubMed Web of Science ®Google Scholar
• Merlo A, Turrini R, Dolcetti R, Zanovello P, Amadori A, Rosato A. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin. Biol. Ther.8(9), 1265–1294 (2008).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis.184(11), 1461–1464 (2001).
   PubMed Web of Science ®Google Scholar
• Razonable RR, van Cruijsen H, Brown RA et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J. Infect. Dis.187(11), 1801–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Humar A, Gregson D, Caliendo AM et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation68(9), 1305–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J. Clin. Microbiol.40(3), 746–752 (2002).
   PubMed Web of Science ®Google Scholar
• Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant.9(2), 258–268 (2009).
   PubMed Web of Science ®Google Scholar
• Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S78–S86 (2009).
   PubMed Web of Science ®Google Scholar
• Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet365(9477), 2105–2115 (2005).
   PubMed Web of Science ®Google Scholar
• Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. (2), CD003774 (2008).
   Google Scholar
• Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med.143(12), 870–880 (2005).
   PubMed Web of Science ®Google Scholar
• Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis.43(7), 869–880 (2006).
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.4(4), 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant.8(1), 158–161 (2008).
   PubMed Web of Science ®Google Scholar
• Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet350(9093), 1729–1733 (1997).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation89(7), 779–795 (2010).
   PubMed Web of Science ®Google Scholar
• Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant.10(5), 1228–1237 (2010).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Limaye AP, Banks M et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann. Intern. Med.152(12), 761–769 (2010).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation81(12), 1645–1652 (2006).
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am. J. Transplant.9(5), 1205–1213 (2009).
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.7(9), 2106–2113 (2007).
   PubMed Web of Science ®Google Scholar
• Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy2(1), 117–130 (2010).
   PubMed Web of Science ®Google Scholar
• Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J. Infect. Dis.181(2), 717–720 (2000).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S97–S100 (2009).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl.8(8), 651–658 (2002).
   PubMed Web of Science ®Google Scholar
• Antman K, Chang Y. Kaposi’s sarcoma. N. Engl. J. Med.342(14), 1027–1038 (2000).
   PubMed Web of Science ®Google Scholar
• Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN. Sirolimus for Kaposi’s sarcoma. J. Heart Lung Transplant.25(6), 726–729 (2006).
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N. Engl. J. Med.352(13), 1317–1323 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation79(10), 1277–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am. J. Transplant.2(1), 25–30 (2002).
   PubMed Web of Science ®Google Scholar
• Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis.199(6), 837–846 (2009).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl. Int.17(11), 658–665 (2005).
   PubMed Web of Science ®Google Scholar
• Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation87(5), 621–630 (2009).
   PubMed Web of Science ®Google Scholar
• Wattier RL, Vazquez M, Weibel C et al. Role of human polyomaviruses in respiratory tract disease in young children. Emerg. Infect. Dis.14(11), 1766–1768 (2008).
   PubMed Web of Science ®Google Scholar
• van der Zalm MM, Rossen JW, van Ewijk BE et al. Prevalence and pathogenicity of WU and KI polyomaviruses in children, The Netherlands. Emerg. Infect. Dis.14(11), 1787–1789 (2008).
   PubMed Web of Science ®Google Scholar
• Gaynor AM, Nissen MD, Whiley DM et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog.3(5), e64 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect. Dis.3(10), 611–623 (2003).
   PubMed Web of Science ®Google Scholar
• Bohl DL, Storch GA, Ryschkewitsch C et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am. J. Transplant.5(9), 2213–2221 (2005).
   PubMed Web of Science ®Google Scholar
• Viscount HB, Eid AJ, Espy MJ et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation84(3), 340–345 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Randhawa P. BK virus in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S136–S146 (2009).
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Hirsch HH, Papadimitriou JC et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation84(3), 323–330 (2007).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Hirsch HH, Faraci M et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin. Infect. Dis.49(2), 233–240 (2009).
   PubMed Web of Science ®Google Scholar
• Faguer S, Hirsch HH, Kamar N et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl. Int.20(11), 962–969 (2007).
   PubMed Web of Science ®Google Scholar
• Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev. Anti Infect. Ther.5(1), 105–115 (2007).
   PubMed Web of Science ®Google Scholar
• Levitsky J, Doucette K. Viral hepatitis in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S116–S130 (2009).
   Google Scholar
• Kamar N, Selves J, Mansuy JM et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N. Engl. J. Med.358(8), 811–817 (2008).
   PubMed Web of Science ®Google Scholar
• Haagsma EB, van den Berg AP, Porte RJ et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl.14(4), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin. Transpl.17–37, (1998).
   Google Scholar
• Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology13(4), 619–626 (1991).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351(15), 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med.329(25), 1842–1847 (1993).
   PubMed Web of Science ®Google Scholar
• Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant. Proc.19(5), 4051–4053 (1987).
   PubMed Web of Science ®Google Scholar
• Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology27(1), 254–263 (1998).
   PubMed Web of Science ®Google Scholar
• Seehofer D, Rayes N, Berg T et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl. Int.13(4), 290–296 (2000).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology28(2), 585–589 (1998).
   PubMed Web of Science ®Google Scholar
• Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am. J. Transplant.3(8), 999–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Beckebaum S, Sotiropoulos GC, Gerken G, Cicinnati VR. Hepatitis B and liver transplantation: 2008 update. Rev. Med. Virol.19(1), 7–29 (2009).
   PubMed Web of Science ®Google Scholar
• Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl.7(6), 513–517 (2001).
   PubMed Web of Science ®Google Scholar
• Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology32(5), 1125–1130 (2000).
   PubMed Web of Science ®Google Scholar
• Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol.41(5), 830–836 (2004).
   PubMed Web of Science ®Google Scholar
• Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology32(4 Pt 1), 852–858 (2000).
   PubMed Web of Science ®Google Scholar
• Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation78(7), 966–971 (2004).
   PubMed Web of Science ®Google Scholar
• de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am. J. Transplant.6(12), 2983–2993 (2006).
   PubMed Web of Science ®Google Scholar
• Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology41(2), 289–298 (2005).
   PubMed Web of Science ®Google Scholar
• Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology124(3), 642–650 (2003).
   PubMed Web of Science ®Google Scholar
• Raza K, Ismailjee SB, Crespo M et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J. Heart Lung Transplant.26(8), 862–864 (2007).
   PubMed Web of Science ®Google Scholar
• Kupfer B, Vehreschild J, Cornely O et al. Severe pneumonia and human bocavirus in adult. Emerg. Infect. Dis.12(10), 1614–1616 (2006).
   PubMed Web of Science ®Google Scholar
• Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am. J. Transplant.3(8), 977–981 (2003).
   PubMed Web of Science ®Google Scholar
• Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J. Heart Lung Transplant.21(5), 559–566 (2002).
   PubMed Web of Science ®Google Scholar
• Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther.12(4 Pt B), 627–638 (2007).
   PubMed Web of Science ®Google Scholar
• Ison MG, Michaels MG. RNA respiratory viral infections in solid organ transplant recipients. Am. J. Transplant.9(Suppl. 4), S166–S172 (2009).
   PubMedGoogle Scholar
• Englund JA. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol. Blood Marrow Transplant.7(Suppl.), 2S–4S (2001).
   PubMed Web of Science ®Google Scholar
• Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant.32(11), 1085–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis.10(8), 521–526 (2010).
   PubMed Web of Science ®Google Scholar
• Sable CA, Hayden FG. Orthomyxoviral and paramyxoviral infections in transplant patients. Infect. Dis. Clin. North Am.9(4), 987–1003 (1995).
   PubMed Web of Science ®Google Scholar
• Vilchez RA, Fung J, Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl. Infect. Dis.4(4), 177–182 (2002).
   PubMedGoogle Scholar
• Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am. J. Transplant.2(3), 287–291 (2002).
   PubMed Web of Science ®Google Scholar
• Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest119(4), 1277–1280 (2001).
   PubMed Web of Science ®Google Scholar
• Scharpe J, Evenepoel P, Maes B et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am. J. Transplant8(2), 332–337 (2008).
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Ikizler MR, Sannella EC et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am. J. Kidney Dis.54(1), 112–121 (2009).
   PubMed Web of Science ®Google Scholar
• Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin. Microbiol. Rev.16(3), 357–364 (2003).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep.57(RR-7), 1–60 (2008).
   PubMedGoogle Scholar
• Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J. Heart Lung Transplant.27(3), 282–288 (2008).
   PubMed Web of Science ®Google Scholar
• Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med.353(13), 1363–1373 (2005).
   PubMed Web of Science ®Google Scholar
• Ison MG, Szakaly P, Shapira M, Krivan G, Nist A, Dutkowski R. Oseltamivir prophylaxis significantly reduces the incidence of seasonal influenza infection in immunocompromised patients. Presented at: XI International Symposium on Respiratory Viral Infections. Bangkok, Thailand, 19–22 February 2009.
   Google Scholar
• Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther.12(4 Pt B), 603–616 (2007).
   PubMed Web of Science ®Google Scholar
• Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis.193(6), 760–764 (2006).
   PubMed Web of Science ®Google Scholar
• Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res.103(1–2), 199–203 (2004).
   PubMed Web of Science ®Google Scholar
• Machado CM, Boas LS, Mendes AV et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant.34(2), 111–114 (2004).
   PubMed Web of Science ®Google Scholar
• Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. J. Infect. Dis.196(2), 181–190 (2007).
   PubMed Web of Science ®Google Scholar
• Krinzman S, Basgoz N, Kradin R et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J. Heart Lung Transplant.17(2), 202–210 (1998).
   PubMed Web of Science ®Google Scholar
• Palmer SM Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral infection in adult lung transplant recipients. Chest113(4), 944–950 (1998).
   PubMed Web of Science ®Google Scholar
• Singhal S, Muir DA, Ratcliffe DA et al. Respiratory viruses in adult liver transplant recipients. Transplantation68(7), 981–984 (1999).
   PubMed Web of Science ®Google Scholar
• Taylor GS, Vipond IB, Caul EO. Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. J. Clin. Microbiol.39(2), 801–803 (2001).
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med.329(21), 1524–1530 (1993).
   PubMed Web of Science ®Google Scholar
• Thomas NJ, Hollenbeak CS, Ceneviva GD, Geskey JM, Young MJ. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J. Pediatr. Hematol. Oncol.29(4), 227–232 (2007).
   PubMed Web of Science ®Google Scholar
• Pelaez A, Lyon GM, Force SD et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J. Heart Lung Transplant.28(1), 67–71 (2009).
   PubMed Web of Science ®Google Scholar
• Glanville AR, Scott AI, Morton JM et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J. Heart Lung Transplant.24(12), 2114–2119 (2005).
   PubMed Web of Science ®Google Scholar
• McGrath D, Falagas ME, Freeman R et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J. Infect. Dis.177(2), 459–462 (1998).
   PubMed Web of Science ®Google Scholar
• Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. J. Thorac. Cardiovasc. Surg.116(4), 617–623 (1998).
   PubMed Web of Science ®Google Scholar
• Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J. Infect. Dis.165(1), 170–174 (1992).
   PubMed Web of Science ®Google Scholar
• Pinchoff RJ, Kaufman SS, Magid MS et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation76(1), 183–189 (2003).
   PubMed Web of Science ®Google Scholar
• Humar A, Kumar D, Mazzulli T et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am. J. Transplant.5(10), 2555–2559 (2005).
   PubMed Web of Science ®Google Scholar
• Koneru B, Atchison R, Jaffe R, Cassavilla A, Van Thiel DH, Starzl TE. Serological studies of adenoviral hepatitis following pediatric liver transplantation. Transplant. Proc.22(4), 1547–1548 (1990).
   PubMed Web of Science ®Google Scholar
• Ison MG, Green M. Adenovirus in solid organ transplant recipients. Am. J. Transplant9(Suppl. 4), S161–S165 (2009).
   PubMed Web of Science ®Google Scholar
• Engelmann G, Heim A, Greil J et al. Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr. Transplant.13(4), 421–428 (2009).
   PubMed Web of Science ®Google Scholar
• Refaat M, McNamara D, Teuteberg J et al. Successful cidofovir treatment in an adult heart transplant recipient with severe adenovirus pneumonia. J. Heart Lung Transplant.27(6), 699–700 (2008).
   PubMed Web of Science ®Google Scholar